Jun 15, 2020
Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference
Jun 04, 2020
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
May 29, 2020
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
May 26, 2020
Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference
May 14, 2020
Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference
May 13, 2020
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
May 06, 2020
Neurocrine Biosciences Reports First Quarter 2020 Financial Results
Apr 27, 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
Apr 15, 2020
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results
Feb 03, 2020
Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors
Jan 20, 2020
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
Jan 06, 2020
Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020
Dec 02, 2019
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
Nov 26, 2019
Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference
Nov 05, 2019
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
Oct 04, 2019
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
Oct 01, 2019
Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
Sep 30, 2019
Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer
Sep 17, 2019
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
Sep 11, 2019
Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors